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Background: Patient’s satisfaction with monitoring frequency is of interest when implementing six-monthly monitoring
for well-controlled type 2 diabetes patients. Here we want to determine the satisfaction of well-controlled type 2
diabetes patients with either three-monthly or six-monthly diabetes monitoring and their future preference.
Methods: Survey among 2215 well-controlled type 2 diabetes patients (not using insulin, HbA1c ≤58 mmol/mol,
systolic blood pressure ≤145 mmHg and total cholesterol ≤5.2 mmol/l) who participated in the EFFIMODI
study, a randomised controlled patient-preference equivalence trial. At baseline, participants were asked
whether they had a strong preference for three-monthly or six-monthly monitoring or not. If not, they were
randomised to either three-monthly or six-monthly monitoring, while the others were monitored according to
their preference. After eighteen months, all participants were asked whether they were satisfied with the
monitoring frequency and about their future preference. Patient characteristics associated with satisfaction
were also examined.
Results: Most patients (70.8%) would like to continue their monitoring frequency. Patients from the preference
groups were more often satisfied than randomised patients (92.7% and 88.1%, respectively) and patients monitored
three-monthly were more often satisfied than patients monitored six-monthly (93.5% and 88.5%, respectively). Higher
age, better physical health, less diabetes-related distress, higher diabetes treatment satisfaction and less perceived
hyper- and hypoglycaemias were associated with a higher monitoring satisfaction.
Conclusions: Most well-controlled type 2 diabetes patients were satisfied with their monitoring frequency and
would like to continue it. Although the satisfaction for three-monthly monitoring was slightly higher, the satisfaction
with six-monthly monitoring was still rather high (88.5%).
Trial registration: Current controlled trials ISRCTN93201802.Background
Worldwide, the number of people with type 2 diabetes
was 366 million in 2011 and this number is likely to
increase with 50% by 2030 [1]. International diabetes
guidelines recommend different monitoring frequencies
ranging from one to four times a year, but these guide-
lines are not evidence-based [2,3]. Here monitoring refers
to the role of the diabetes care provider who regularly
checks the health status of the patient, the cardiometabolic
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distribution, and reproduction in any mediumIf part of the patients with diabetes would visit their
general practice less frequently, this could lessen the
patients’ and health care providers’ diabetes-related
burden and provide savings in healthcare costs. We
could demonstrate that six-monthly monitoring of
well-controlled diabetes patients who had no strong
preference with regard to their diabetes monitoring
frequency in primary care achieved comparable cardio-
metabolic control compared to three-monthly monitoring
(submitted).
However, two out of three patients had a strong pref-
erence with regard to the monitoring frequency [4].
These preferences might hamper the implementation oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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ferred treatment may have better compliance and be
more motivated to follow treatment regimens [5,6].
Besides costs savings, the satisfaction of the patients
with their monitoring frequency is of interest when
implementing six-monthly monitoring, since patient sat-
isfaction is associated with treatment adherence [7,8].
To our knowledge, no research has been performed on
satisfaction with monitoring frequency and which factors
are associated with it.
Therefore, we aimed to assess patient’s satisfaction
with either three-monthly or six-monthly diabetes moni-
toring after eighteen months of experience in both pa-
tients with and without a strong preference at the start
of that period. We also determined which patient char-
acteristics and health-related factors are associated with
this satisfaction and what patients prefer for the future
with regard to their diabetes monitoring.
Methods
Study design and patients
This study is part of a randomised controlled patient-
preference equivalence trial in primary care. Type 2
diabetes patients were recruited in general practices
across the Netherlands from April 2009 to August
2010. Patients were eligible if between 40 and 80 years old,
diagnosed with type 2 diabetes for more than a year,
treated by their general practitioner, not on insulin
treatment and overall well-controlled, defined as having
HbA1c ≤58 mmol/mol (≤7.5%), systolic blood pres-
sure ≤145 mmHg and total cholesterol ≤5.2 mmol/l.
We have chosen values a little higher than the currently
used targets in the Netherlands [9] in order to create a lar-
ger target population.
Eligible patients were contacted by mail by their gen-
eral practitioner with an information letter and an in-
formed consent form. At baseline, patients were asked
whether they had a strong preference for three-monthly
or six-monthly monitoring. Those with a strong prefer-
ence for either three-monthly or six-monthly monitor-
ing were treated according to their preference, while
those without a strong preference were randomised to
either three-monthly or six-monthly monitoring. After
returning the informed consent form, all participants re-
ceived a postal questionnaire to be completed at home
and after eighteen months they received the end-of-study
questionnaire.
The study was approved by the Medical Research
Ethics Committee of the University Medical Center
Utrecht (protocol number 08–453). A detailed protocol of
the EFFIMODI study has been published elsewhere [10].
In this paper we describe the satisfaction of well-controlled
type 2 diabetes patients with three-monthly and six-
monthly monitoring.Measurement of patient’s satisfaction and preference for
the monitoring frequency in the future
In the end-of-study questionnaire, the following two
questions were included:
1) How satisfied were you with either three-monthly
or six-monthly monitoring? (not at all, not, neutral,
moderate, very much)
2) How often would you like to be monitored in
the future? (every three months, every six months,
no preference/I do not care, every (filled in by the
patient) months)
Measurement of determinants of patient’s satisfaction
Several possible determinants of patient’s satisfaction
were assessed. These were derived from the patient
questionnaires or from the medical data collected by a
case report form filled in by the general practitioner or
practice nurse.
Both the baseline and end-of-study questionnaire in-
cluded information on age, gender, smoking, health sta-
tus (measured with the SF-36 [11] and EQ VAS [12]),
diabetes-related distress (measured with the PAID [13])
and satisfaction with diabetes treatment and experi-
enced hyper- or hypoglycaemias (measured with the
DTSQ status [14]).
The case report form consisted of information on the
year of diabetes diagnosis and comorbidities at baseline
(myocardial infarction, angina pectoris, heart surgery,
heart failure, stroke, transient ischemic attack, peripheral
arterial disease, COPD, rheumatoid arthritis, osteoarth-
ritis of hip or knee or any other diseases). Furthermore,
we used the last known measurement of HbA1c, HDL,
LDL and total cholesterol levels as well as baseline and
final measurements of blood pressure and weight.
Statistical analysis
Descriptive statistics were used to describe the satis-
faction with the monitoring frequency and preference
for future monitoring frequency for each study group.
For the future monitoring frequency the answers of
the second question were categorised into: frequent
(every 1–4 months), infrequent (every ≥ 5 months) and
does not care.
Then the answers to the first question were categorised
into: (very) satisfied, neutral and not (at all) satisfied. The
chi square test was used to examine if satisfaction differed
between the three-monthly and six-monthly groups (both
with and without a preference) and between the preference
and randomised groups (both three-monthly and six-
monthly monitoring).
Since the group who chose ‘not (at all) satisfied’ was
small, this was combined with ‘neutral’ to compare the
differences in patient characteristics and health-related
factors between patients who were satisfied and those
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variables and linear regression for continuous variables
to demonstrate the association between satisfaction and
patient characteristics and health-related factors. In
addition, we added the four study groups as interaction
terms to the regression models. If not significant, study
group was added to the regression model as confounder.
Data were analysed with SPSS version 20.
Results
Of the 4040 patients who were invited to participate,
2215 (54.8%) agreed. Participants had a mean age of 64
years (SD=9) at the start of the study period, 1311 (59%)
were male and the mean duration of diabetes was six
years (SD=4). Of all participants, 747 patients (33.7%)
preferred three-monthly monitoring, 677 (30.6%) preferred
six-monthly monitoring, 394 (17.8%) were randomised to
three-monthly and 397 (17.9%) to six-monthly monitoring
at baseline (Table 1).
Satisfaction with the monitoring frequency
In Table 1 the satisfaction with the monitoring frequency
per study group is shown. Patients from the preference
groups were more often (very) satisfied compared to
those who were randomised (92.7% and 88.1%, respect-
ively; p=0.001) and patients from the three-monthly
groups were more often (very) satisfied with their moni-
toring frequency compared to those in the six-monthly
groups (93.5% and 88.5%, respectively; p<0.001).
Satisfaction with diabetes treatment (DTSQ) did not
differ between the four study groups (ANOVA, p=0.454).
The three-monthly preference group had a score of 31.8,
the six-monthly preference group of 32.2, the randomised
three-monthly group of 31.9 and the six-monthly group
of 31.8.Table 1 Number (%) of patients who are satisfied with the m







n (%) n (%)
Very satisfied 291 (46.3%) 206 (35.6%
Satisfied 303 (48.2%) 318 (55.0%
Neutral 29 (4.6%) 39 (6.7%
Not satisfied 3 (0.5%) 12 (2.1%
Not at all satisfied 2 (0.3%) 3 (0.5%)
Preference for future
monitoring
Frequent (every 1–4 months) 545 (86.6%) 87 (15.0%
Infrequent (every ≥5 months) 54 (8.6%) 445 (76.6%
Does not care 30 (4.8%) 49 (8.4%Preference for the monitoring frequency in the future
Most patients (70.8%) would like to continue their moni-
toring frequency. 11.1% did not care about their future
monitoring frequency and the remainder preferred ei-
ther a more (10.8%) or less (7.2%) frequent monitoring
in the future.
Patients who received their preferred monitoring fre-
quency were more likely to insist on continuing their pre-
ferred monitoring frequency in the future, both in the
three-monthly group (86.6%) and in the six-monthly group
(76.6%) (Table 1). Only 19.1% of the patients who did not
have a preference at baseline still did not care about the
monitoring frequency in the future after their eighteen
months of experience in the trial. The patients who were
randomised to either three-monthly or six-monthly moni-
toring were more likely to prefer the monitoring frequency
they were assigned to, although this effect was slightly
stronger in the three-monthly monitoring group.
Patient characteristics associated with satisfaction with
the monitoring frequency
Satisfaction with the monitoring frequency was associated
with: higher age, a better physical health, less diabetes-
related distress, higher diabetes treatment satisfaction, less
experienced hyper- and hypoglycaemias and a lower LDL
and diastolic blood pressure (Table 2). No interaction by
study group was observed in the association between
satisfaction and patient characteristics and health-related
factors. Besides, adding study group as a confounder to
the models did not alter the results. Therefore, we only
reported the crude p-values.
Discussion
This study showed that most well-controlled type 2
diabetes patients were satisfied with their monitoringonitoring frequency and how often they want to be




n (%) n (%)
) 106 (30.3%) 98 (28.1%)
) 214 (61.1%) 198 (56.7%)
) 25 (7.1%) 38 (10.9%)
) 4 (1.1%) 10 (2.9%)
1 (0.3%) 5 (1.4%)
) 203 (57.8%) 120 (34.4%)
) 84 (23.9%) 159 (45.6%)
) 64 (18.2%) 70 (20.1%)
Table 2 Satisfaction with the monitoring frequency (n=1905)
Not satisfied n=171 Satisfied n=1734
n Mean ± SD or n (%) n Mean ± SD or n (%) P-value
Age at baseline 171 62.5 ± 8.9 1734 64.6 ± 8.6 0.003
Gender, male 171 111 (64.9%) 1734 1029 (59.3%) 0.156
One or more comorbidities at baseline 171 69 (40.4%) 1734 646 (37.3%) 0.425
Duration of diabetes (in years) 167 5.6 ± 3.3 1695 5.9 ± 3.7 0.283
Current smoker* 165 35 (21.2%) 1672 251 (15.0%) 0.137
SF-36 PCS [scale: 0–100]* 137 44.7 ± 10.4 1414 45.7 ± 10.5 0.027
SF-36 MCS [scale: 0–100]* 137 51.5 ± 10.5 1414 54.1 ± 8.7 0.407
EQ VAS [scale: 0–100]* 155 71.7 ± 13.8 1510 75.2 ± 14.7 0.100
PAID [scale: 0–80]* 152 10.3 ± 11.8 1539 6.5 ± 9.0 <0.001
DTSQ [scale: 0–36]* 158 26.8 ± 6.4 1607 32.4 ± 4.1 <0.001
DTSQ hyper [scale: 0–6]* 166 2.2 ± 1.9 1650 1.3 ± 1.7 <0.001
DTSQ hypo [scale: 0–6]* 166 1.3 ± 1.6 1652 0.8 ± 1.4 0.001
HbA1c (mmol/mol)** 160 49.3 ± 6.8 1656 48.2 ± 7.5 0.077
HDL cholesterol (mmol/l)** 159 1.2 ± 0.3 1637 1.2 ± 0.3 0.089
LDL cholesterol (mmol/l)** 159 2.4 ± 0.8 1634 2.3 ± 0.7 0.044
Total cholesterol (mmol/l)** 159 4.3 ± 0.9 1633 4.2 ± 0.8 0.069
Systolic blood pressure (mmHg)* 130 132.9 ± 15.1 1477 134.0 ± 14.7 0.680
Diastolic blood pressure (mmHg)* 130 78.1 ± 9.9 1474 76.3 ± 9.2 0.025
BMI (kg/m2)* 120 29.1 ± 4.2 1373 29.1 ± 4.8 0.609
* Final measurement, corrected for baseline measurement.
** Last known measurement during follow-up.
SF-36 Short-Form 36, PCS Physical Component Score, MCS Mental Component Score, EQ VAS EuroQol Visual Analogue Scale, PAID Problem Areas In Diabetes, DTSQ
Diabetes Treatment Satisfaction Questionnaire status.
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isation. Besides, the majority would like to continue this
frequency in the future. Patients being monitored three-
monthly or according to their preference tended to be
more satisfied. On the other hand, most patients assigned
to their study group by randomisation wished to con-
tinue the assigned monitoring frequency in the future.
Overall, patients were satisfied with their monitoring
frequency in our study. Despite this, patients who deter-
mined their own monitoring frequency were more satis-
fied. Therefore, in order to increase patient’s satisfaction,
patient’s preferences should be taken into account. How-
ever, currently the monitoring frequency is mostly deter-
mined by the physician in patients with chronic diseases
[15-18]. Patients usually prefer a slightly less frequent
monitoring compared to physicians [19] or as deter-
mined by guidelines [20]. This leads to the question: to
whom should we listen?
A study in haemodialysis care showed that patients
with less frequent patient-physician contact were less
satisfied with their monitoring frequency, although no
difference in satisfaction with overall quality of care was
found [21]. A randomised equivalence trial comparing
three-monthly and six-monthly monitoring in patientswith hypertension in primary care showed no significant
differences on satisfaction with care [22], although more
patients in the six-monthly group thought that their
general practitioner did not take their blood pressure
problem seriously enough. In accordance with these
studies, we also observed that the prevalence of satisfied
patients was slightly higher among those randomised to
three-monthly monitoring than those randomised to six-
monthly monitoring. However, we have also measured
satisfaction with the diabetes treatment, which is more
comparable to the score used by Birtwhistle et al. Using
this score, we could not detect any significant differences
between the four study groups. So based on this, the pa-
tients who are monitored six-monthly are satisfied with
the overall care, although they indicated to be slightly
less satisfied with the monitoring frequency than those
randomised to three-monthly monitoring.
Patients who had a lower physical health, a higher
diabetes-related distress and perceived more hyper- and
hypoglycaemias were less satisfied with the monitor-
ing frequency. We also found significant differences
for LDL cholesterol and diastolic blood pressure, but
the absolute differences were very small. So it seems
that well-controlled type 2 diabetes patients based their
Wermeling et al. BMC Family Practice 2013, 14:107 Page 5 of 6
http://www.biomedcentral.com/1471-2296/14/107dissatisfaction with the monitoring frequency on logical
reasons. This is in concordance with the preferences of the
patients at baseline, where we showed that patients seem
to make logical choices regarding the monitoring fre-
quency [4]. These results confirm that patients themselves
should also be involved in determining the monitoring fre-
quency. One out of three had a strong preference for
three-monthly monitoring and therefore, this should be
taken into account.
A major advantage is that treating patients according
their preference might improve treatment adherence and
thus clinical outcomes [23]. Especially in diabetes care
this is of utmost importance, since patients have to deal
with treatment adherence and self-management to keep
their diabetes under control. This could be achieved by
discussing the preferred monitoring frequency with the
patient on a structured annual basis. Besides, general
practitioners might discuss with the patient their satis-
faction with the monitoring frequency.
One of the strengths of this study is that we included
a large number of type 2 diabetes patients. Furthermore,
extensive patient data were available providing the op-
portunity to explore both patient characteristics and
health-related factors in relation to patient satisfaction.
However, it is unknown whether additional patient fac-
tors may influence the satisfaction with the monitoring
frequency. Unfortunately, we were unable to take un-
known variables (such as travel time to the general prac-
tice, mean time in the waiting room, mean duration of
the visits, compliance to therapy, knowledge of type 2
diabetes and patients’ coping strategies) into account.
Another limitation is that some patients might have mis-
understood the question on the monitoring frequency.
Some patients may have indicated how satisfied they
were with the content of the visits instead of with the
number of visits. This would also explain some ‘implaus-
ible’ answers. For example, 261 patients (13.7%) who
liked their monitoring frequency preferred another fre-
quency in the future and 17 patients (0.9%) who disliked
their monitoring frequency chose the same frequency in
the future (data not shown). However, we believe that
because of the low percentage of these inconsistencies,
this will not have influenced the direction of our results.
Another limitation is that we included only well-
controlled patients. However, well-controlled patients
are the target population for a looser monitoring interval
(every six months) as opposed to more "problematic"
diabetes patients, who may require more frequent visits.
Of course diabetes monitoring regards more parameters
than HbA1c, blood pressure or cholesterol such as kidney
function, micro-albuminuria, micro- and macrovascular
complications and health related quality of life. We could
demonstrate that in our study population comorbidities
were strongly related to health status [24]. These aspectsshould be monitored in all patients during a longer annual
check-up. Obviously the presence or deterioration of any
of these parameters may justify a more intensive monitor-
ing frequency.
Conclusions
Based on the results we conclude that it is feasible to
implement six-monthly monitoring in well-controlled
type 2 diabetes patients. We have shown that patient’s
preferences should be taken into account to increase pa-
tient’s satisfaction. Although the satisfaction for three-
monthly monitoring was higher than in six-monthly
monitoring, the satisfaction with six-monthly monitoring
was still rather high (88.5%). We expect that at least two
out of three well-controlled type 2 diabetes patients can
be eligible for six-monthly monitoring.
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